The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MPN Workshop of the Carolinas 2024 | Using momelotinib in MF with anemia: dosing and switching from ruxolitinib
Momelotinib was approved in 2023 for the treatment of patients with intermediate or high-risk myelofibrosis (MF) and anemia in both the frontline and relapsed settings. Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines how this agent should be dosed, highlights the common adverse events observed, and provides insight into switching patients from ruxolitinib to momelotinib. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support: Incyte, BMS, CTI (Sobi), Morphosys, Karyopharm, Sumitomo, Ajax, Disc, Ionis, Geron, Janssen, Cogent, Blueprint, Kartos, Telios.; Honoraria/consulting fees: Incyte, BMS, CTI (Sobi), GSK, Abbvie, Morphosys, Pharma Essentia, Sumitomo, Karyopharm, Ionis, Disc, Geron, Morphic, Jubilant, Ono, Novartis, Blueprint, Cogent.
